Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1485-1488

  Van Heeckeren, Willem J ^a   Bhakta, Shyam ^a   Ortiz, Jose ^a   Duerk, Jeff ^a   Cooney, Matthew M ^a   Dowlati, Afshin ^a   McCrae, Keith ^a   Remick, Scot C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AURISTATIN PE; BEVACIZUMAB; COMBRETASTATIN A4 PHOSPHATE; EXHERIN; MN 029; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; N ACETYLCOCHINOL O PHOSPHATE; N-ACETYLCOCHINOL-O-PHOSPHATE; ORGANOPHOSPHORUS COMPOUND;

ACUTE CORONARY SYNDROME; ALOPECIA; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; EDITORIAL; FLUSHING; HEART CONDUCTION; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE STRAIN; HEART RATE; HOT FLUSH; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG EMBOLISM; MUCOSA INFLAMMATION; MUSCLE STRAIN; NEUROPATHY; NONHUMAN; PAIN; PERICARDITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; STOMATITIS; THROMBOPHLEBITIS; DRUG EFFECT; ENDOTHELIUM CELL; HEART; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; ENDOTHELIAL CELLS; HEART; HUMANS; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 33645728030     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.8801     Document Type: Editorial

References (26)

1. Beerepoot LV, Radema SA, Witteveen EO, et al: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498, 2006
2. Jeremias A, Gibson CM: Narrative review: Alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 142:786-791, 2005
3. Remick SC, Cooney MM, Tolcher AW, et al: Current development of vascular targeting agents in: ASCO Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2005, pp 212-216
4. Cooney MM, Ortiz J, Bukowski RM, et al: Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds. Curr Oncol Rep 7:90-95, 2005
5. Dokainish H, Pillai M, Murphy SA, et al: Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy. J Am Coll Cardiol 45:19-24, 2005
6. Wu AH: Markers for early detection of cardiac diseases. Scand J Clin Lab Invest Suppl 240:112-121, 2005
7. Mutin M, Canavy I, Blann A, et al: Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 9:2951-2958, 1999
8. Monestroli S, Mancuso P, Burlini A, et al: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 61:4341-4344, 2001
9. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661, 2001
10. Shaked Y, Bertolini F, Man S, et al: Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101-111, 2005
11. Schuch G, Heymach JV, Nomi M, et al: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63:8345-8350, 2003
12. Celik I, Sürücü O, Dietz C, et al: Therapeutic efficacy of endostatin exhibits a biphasic dose response curve. Cancer Res 65:11044-11050, 2005
13. Heymach JV, Kulke MH, Fuchs S, et al: Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin. Proc Am Soc Clin Oncol 22:2004, 2003
14. Yee KW, Hagey A, Vesrtovsek S, et al: Phase I study of ABT-751, a novel microtubule inhibitor, in patients with hematologic malignancies. Clin Cancer Res 11:6615-6624, 2005
15. Beaudry P, Force J, Naumov GN, et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11:3514-3522, 2005
16. Hill JM, Zalos G, Halcox JP, et al: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600, 2003
17. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imag 10:254-259, 1999
18. Evelhoch JL, LoRusso PM, He Z, et al: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657, 2004
19. DelProposto Z, LoRusso PM, Latif Z, et al: MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 20:111a, 2002 (abstract nos. 440)
20. Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416, 2002
21. Galbraith SM, Rustin GJS, Lodge MA, et al: Effects of 5,6-dimethylxanthenone-4-acetic acid on tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840, 2002
22. O'Dwyer PJ, Rosen M, Gallagher M, et al: Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 23:193s, 2005
23. Cooney MM, Radivoyevitch T, Dowlati A, et al: Cardiovascular safety profile of combretastatin A4 phosphate (CA4P) in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10:96-100, 2004
24. Varterasian M, Fingert H, Agin M, et al: Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer. Clin Cancer Res 10:5967-5968, 2004
25. Cooney M, Radivoyevitch T, Dowlati A, et al: Invited Letter to the Editor in response to Varterasian, M., et al: Letter / commentary on the cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I trial in patients with advanced cancer [Clin Cancer Res 10:96-100, 2004]. Clin Cancer Res 10:5968-5969, 2004
26. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005